Patents by Inventor David P Bartels
David P Bartels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130293840Abstract: A device and method for connecting a camera to a scoping apparatus for viewing and taking photos of an eye-ball or other object imaged by the scoping apparatus. A case receives a compact high-resolution camera, and an attachment is connected to the case. The attachment is detachably connected to an eye-piece of the scoping apparatus in a manner to allow passage of an image from the scoping apparatus through the device to the camera for viewing and taking of photos thereof. A sleeve portion of the attachment and the eye-piece have generally the same diameter to allow the attachment sleeve to be fitted over the eye-piece. When the attachment sleeve and eye-piece have different diameters, an adapter having a generally cylindrical shape and a thickness equal generally to the difference in thicknesses is received on the eye-piece and the attachment sleeve received on the adapter to couple the attachment to the eye-piece.Type: ApplicationFiled: April 15, 2013Publication date: November 7, 2013Inventor: David P Bartels
-
Patent number: 8552171Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: GrantFiled: October 4, 2010Date of Patent: October 8, 2013Assignees: University of Massachusetts, Whitehead Insititute for Biomedical Research, Massachusetts Institute of Technology, Max-Planck-Gesellschaft zur Föderung der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 8420391Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: GrantFiled: October 4, 2010Date of Patent: April 16, 2013Assignees: University of Massachusetts, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 8394628Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: GrantFiled: October 4, 2010Date of Patent: March 12, 2013Assignees: University of Massachusetts, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20120309073Abstract: The invention provides budding yeast that have a functional RNAi pathway. The invention provides RNAi pathway polypeptides derived from budding yeast that have an endogenous RNAi pathway. In some embodiments the invention provides functional budding yeast Dicer polypeptides and variants thereof. In some embodiments the invention provides functional budding yeast Argonaute polypeptides and variants thereof. Also provided are isolated nucleic acids encoding the polypeptides of the invention, vectors comprising such nucleic acids, and methods of making the polypeptides and nucleic acids. The invention further provides genetically engineered cells that comprise a functional RNAi pathway polypeptide derived from budding yeast. In some embodiments such cells lack a functional endogenous RNAi pathway and are genetically engineered to have a functional RNAi pathway by introducing nucleic acid(s) encoding one or more functional RNAi pathway polypeptides derived from budding yeast.Type: ApplicationFiled: September 10, 2010Publication date: December 6, 2012Applicants: Whitehead Institute for Biomedical Research, of Queen Elizabeth Near DublinInventors: David P. Bartel, Ines A. Drinnenberg, David E. Weinberg, Kathleen T. Xie, Kenneth H. Wolfe, Gerald Fink
-
Publication number: 20120122111Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: March 9, 2011Publication date: May 17, 2012Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 8143480Abstract: This invention relates to methods for knock-down of a target gene in plants, particularly efficient and specific methods for knock-down of a target gene in plants. This invention also relates to methods for silencing endogenous plant genes or plant pathogen genes. It further relates to nucleic acid constructs (DNA, RNA) which comprise a nucleic acid sequence that corresponds to a target gene or fragment thereof flanked by two complementary sites to an smRNA, e.g., a miRNA (one complementary site is on either side of the nucleic acid sequence), resulting in, for example the configuration: complementary site—nucleic acid sequence that corresponds to a target gene—complementary site.Type: GrantFiled: October 19, 2007Date of Patent: March 27, 2012Assignee: Whitehead Institute for Biomedical ResearchInventors: Michael Axtell, David P. Bartel
-
Publication number: 20120029061Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: February 2, 2012Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20120015042Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: January 18, 2011Publication date: January 19, 2012Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110289611Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: November 24, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110281931Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: November 17, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110244568Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: October 6, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110244446Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: October 6, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20110245318Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: October 4, 2010Publication date: October 6, 2011Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20100253535Abstract: A key fob is provided that includes a housing, a key function operative with a vehicle ignition for allowing operation of the vehicle, and a communication link for allowing communication between the key fob and the vehicle. The key fob also includes memory storing audio files. The audio files may be downloaded or streamed to a vehicle via the communication link. The memory may further store saved audio file information, such as music identifiers, provided on board the vehicle and downloaded to the key fob upon initiation by a user.Type: ApplicationFiled: April 1, 2009Publication date: October 7, 2010Applicant: DELPHI TECHNOLOGIES, INC.Inventors: STEVEN P. THOMAS, DAVID P. BARTEL
-
Publication number: 20090186843Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: July 19, 2007Publication date: July 23, 2009Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20090172838Abstract: This invention relates to methods for knock-down of a target gene in plants, particularly efficient and specific methods for knock-down of a target gene in plants. This invention also relates to methods for silencing endogenous plant genes or plant pathogen genes. It further relates to nucleic acid constructs (DNA, RNA) which comprise a nucleic acid sequence that corresponds to a target gene or fragment thereof flanked by two complementary sites to an smRNA, e.g., a miRNA (one complementary site is on either side of the nucleic acid sequence), resulting in, for example the configuration: complementary site—nucleic acid sequence that corresponds to a target gene—complementary site.Type: ApplicationFiled: October 19, 2007Publication date: July 2, 2009Applicant: Whitehead Institute for Biomedical ResearchInventors: Michael Axtell, David P. Bartel
-
Publication number: 20080132461Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: July 19, 2007Publication date: June 5, 2008Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderung derInventors: Thomas Tuschi, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 6716973Abstract: Engineered mRNA useful in producing libraries of engineered mRNAs, polypeptide-engineered mRNA conjugates and diverse encoded polypeptide libraries, as well as novel ribozymes that join an mRNA to the translation product of the mRNA and methods of identifying members of diverse encoded polypeptide libraries which exhibit a desired activity. Also described are polypeptide-nucleic acid tag conjugates, methods of producing the conjugates and uses therefor.Type: GrantFiled: June 20, 2002Date of Patent: April 6, 2004Assignee: Whitehead Institute for Biomedical ResearchInventors: Donald Scott Baskerville, David P. Bartel
-
Publication number: 20040038273Abstract: Disclosed are tRNA analogues which comprise a tRNA, such as tRNAphe; a nonstandard amino acid moiety which acts as an acceptor substrate, but not as a donor substrate, for ribosome-directed nonstandard polymer transfer and, thus, is stably linked to the acceptor stem of the tRNA; and a reactive or activatible moiety near or within the anticodon stem loop of the tRNA that can medidate the covalent coupling of the tRNA analogue to mRNA. Also disclosed are nonstandard polymer-tRNA analogue-mRNA fusions; libraries of encoded nonstandard polymers; methods of producing and screening the libraries; and target members and their uses.Type: ApplicationFiled: June 17, 2003Publication date: February 26, 2004Applicant: Whitehead Institute for Biomedical ResearchInventors: Charles E. Merryman, David P. Bartel